MX369877B - Composiciones y metodos. - Google Patents

Composiciones y metodos.

Info

Publication number
MX369877B
MX369877B MX2015009991A MX2015009991A MX369877B MX 369877 B MX369877 B MX 369877B MX 2015009991 A MX2015009991 A MX 2015009991A MX 2015009991 A MX2015009991 A MX 2015009991A MX 369877 B MX369877 B MX 369877B
Authority
MX
Mexico
Prior art keywords
compositions
methods
competent
disorders
prevention
Prior art date
Application number
MX2015009991A
Other languages
English (en)
Spanish (es)
Other versions
MX2015009991A (es
Inventor
Von Maltzahn Geoffrey
R HENN Matthew
a berry David
Cook David
G Aunins John
Mckenzie Gregory
Lombardo Mckenzie Mary-Jane
Vulic Marin
Goodman Brian
Winkler Jonathan
Original Assignee
Seres Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Therapeutics Inc filed Critical Seres Therapeutics Inc
Publication of MX2015009991A publication Critical patent/MX2015009991A/es
Publication of MX369877B publication Critical patent/MX369877B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2015009991A 2013-02-04 2014-02-04 Composiciones y metodos. MX369877B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361760574P 2013-02-04 2013-02-04
US201361760585P 2013-02-04 2013-02-04
US201361760584P 2013-02-04 2013-02-04
US201361760606P 2013-02-04 2013-02-04
US201461926918P 2014-01-13 2014-01-13
PCT/US2014/014745 WO2014121302A2 (en) 2013-02-04 2014-02-04 Compositions and methods

Publications (2)

Publication Number Publication Date
MX2015009991A MX2015009991A (es) 2016-02-05
MX369877B true MX369877B (es) 2019-11-25

Family

ID=51263061

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009991A MX369877B (es) 2013-02-04 2014-02-04 Composiciones y metodos.
MX2019014045A MX2019014045A (es) 2013-02-04 2015-08-03 Composiciones y metodos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019014045A MX2019014045A (es) 2013-02-04 2015-08-03 Composiciones y metodos.

Country Status (13)

Country Link
US (14) US10064900B2 (enExample)
EP (5) EP2953474A4 (enExample)
JP (6) JP6479685B2 (enExample)
KR (3) KR20230110367A (enExample)
CN (2) CN105451561A (enExample)
AU (7) AU2014212003C1 (enExample)
BR (2) BR112015018625A2 (enExample)
CA (3) CA2899926C (enExample)
HK (3) HK1218837A1 (enExample)
MX (2) MX369877B (enExample)
NZ (1) NZ711771A (enExample)
RU (1) RU2664479C2 (enExample)
WO (3) WO2014121301A1 (enExample)

Families Citing this family (359)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
EP4663746A3 (en) 2010-02-01 2026-04-15 Ferring Microbiome Inc. Bacteriotherapy for clostridium difficile colitis
EP3040425B1 (en) * 2010-02-17 2019-08-28 Gen-Probe Incorporated Compostions and methods to detect atopobium vaginae nucleic acid
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
CN110055320A (zh) * 2012-03-17 2019-07-26 加州大学评议会 痤疮的快速诊断和个体化治疗
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
JP2015522554A (ja) 2012-06-04 2015-08-06 サンコー・エナジー・インコーポレーテッド パラフィン油及び沈降防止剤を含む製剤
CN114949001A (zh) 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP2016519664A (ja) * 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
ES2664411T3 (es) 2013-03-15 2018-04-19 Suncor Energy Inc. Composiciones herbicidas
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
EP3536168A3 (en) 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
US9783858B2 (en) * 2014-04-02 2017-10-10 Northwestern University Altered microbiome of chronic pelvic pain
US10766799B2 (en) 2014-05-23 2020-09-08 Nch Corporation Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method
FI127671B (en) 2014-05-28 2018-11-30 Filip Scheperjans Method for diagnostics of Parkinson’s disease
US20160016002A1 (en) * 2014-07-17 2016-01-21 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Probiotics
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
GB201413333D0 (en) * 2014-07-28 2014-09-10 Azotic Technologies Ltd Plant inoculation
PL3194566T3 (pl) * 2014-08-04 2019-09-30 Basf Se Przeciwgrzybicze szczepy paenibacillus, związki typu fuzarycydyny i ich zastosowanie
WO2016036839A1 (en) * 2014-09-02 2016-03-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
US10900043B2 (en) 2014-09-02 2021-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating bacterial disease
JP6487534B2 (ja) 2014-09-05 2019-03-20 シンビオミックス セラピューティクス、エルエルシー 細菌性膣炎の治療に使用するためのセクニダゾール
WO2016057671A1 (en) * 2014-10-07 2016-04-14 University Of Virginia Patent Foundation Compositions and methods for preventing and treating infection
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
KR20170086492A (ko) 2014-10-30 2017-07-26 캘리포니아 인스티튜트 오브 테크놀로지 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
ES3010296T3 (en) * 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
WO2016103005A1 (en) 2014-12-23 2016-06-30 Institut Pasteur Method of culturing segmented filamentous bacteria in vitro
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
AU2016215209A1 (en) * 2015-02-06 2017-07-20 Western University Of Health Sciences Probiotic compositions and methods of use
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US20180050070A1 (en) * 2015-03-12 2018-02-22 The University Of British Columbia Bacterial compositions and methods of use thereof
US10500236B2 (en) * 2015-03-16 2019-12-10 Ecole Polytechnique Federale De Lausanne (Epfl) Bioactive animal feed
CN107849564A (zh) 2015-04-03 2018-03-27 奎斯特诊断投资股份有限公司 用于检测致病性钩端螺旋体菌株的测定
CN107708716B (zh) * 2015-04-13 2022-12-06 普梭梅根公司 用于微生物组分类学特征相关的状况的微生物组来源的诊断和治疗的方法及系统
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
EP3283084B1 (en) * 2015-04-13 2025-08-06 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
EP3283086A4 (en) * 2015-04-13 2019-04-24 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMY-DERIVED DIAGNOSTICS AND THERAPEUTIC FOR DISEASES RELATED TO MICROBIOMIC FUNCTIONAL PROPERTIES
CN107708714B (zh) * 2015-04-14 2022-07-22 普梭梅根公司 用于内分泌系统状况的微生物组来源的诊断和治疗的方法及系统
FR3035328B1 (fr) 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
US12050161B2 (en) 2015-04-24 2024-07-30 Maat Pharma Microorganism sampling method, microorganism sampling device and sampling kit comprising such a sampling device
FR3035317B1 (fr) 2015-04-24 2019-06-14 Maat Pharma Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif
CN114159476A (zh) * 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
CN114366759A (zh) * 2015-05-22 2022-04-19 亚利桑那大学董事会 用于治疗自闭症谱系障碍及相关症状的方法
US11253501B2 (en) 2015-06-01 2022-02-22 Lupin Inc. Secnidazole formulations and use in treating bacterial vaginosis
CN105067731B (zh) * 2015-06-05 2017-06-16 中国农业科学院兰州兽医研究所 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
PL3307289T3 (pl) 2015-06-09 2022-01-17 Rebiotix, Inc. Sposoby wytwarzania kompozycji do terapii przywracającej mikrobiotę (mrt)
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180243A1 (es) * 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
WO2018126026A1 (en) 2016-12-28 2018-07-05 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US10632157B2 (en) 2016-04-15 2020-04-28 Ascus Biosciences, Inc. Microbial compositions and methods of use for improving fowl production
ES2978111T3 (es) 2015-06-25 2024-09-05 Native Microbials Inc Métodos, aparatos y sistemas para analizar cepas de microorganismos de comunidades heterogéneas complejas, predecir e identificar relaciones funcionales e interacciones de las mismas, y seleccionar y sintetizar conjuntos microbianos basados en las mismas
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
US20180200308A1 (en) * 2015-07-08 2018-07-19 Seres Therapeutics, Inc. Methods of treating colitis
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017035188A1 (en) * 2015-08-24 2017-03-02 Nubyiota Llc Systems and methods for treating a dysbiosis using fecal-derived bacterial populations
JP2018531908A (ja) 2015-09-04 2018-11-01 メモリアル スローン ケタリング キャンサー センター 癌の再発のリスクを検出するための方法及び組成物
AU2016321333A1 (en) * 2015-09-09 2018-04-26 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
US20190216861A1 (en) * 2015-09-22 2019-07-18 Mayo Foundation For Medical Education And Research Methods and materials for using biomarkers which predict susceptibility to clostridium difficile infection
JP2018535653A (ja) * 2015-09-24 2018-12-06 アグリカルチャー ビクトリア サービシーズ プロプライエタリー リミテッド ブラキナリア属内生菌及び関連する方法
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
KR20180093903A (ko) 2015-11-03 2018-08-22 더 브리검 앤드 우먼즈 하스피털, 인크. 음식 알레르기의 치료 및/또는 예방을 위한 치료용 미생물총
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
WO2017100420A1 (en) * 2015-12-08 2017-06-15 Mayo Foundation For Medical Education And Research Biomarkers for predicting clostridium difficile infection treatment outcome
FR3045383B1 (fr) * 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
PL3400285T3 (pl) 2016-01-07 2026-05-25 Native Microbials, Inc. Sposoby poprawy wytwarzania mleka poprzez podawanie konsorcjów mikrobiologicznych
CN106974940B (zh) * 2016-01-15 2020-08-25 深圳华大生命科学研究院 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
IL243707A0 (en) * 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
RS64782B1 (sr) * 2016-02-04 2023-11-30 Univ Gent Upotreba mikrobnih zajednica za zdravlje ljudi i životinja
WO2017137834A1 (en) * 2016-02-08 2017-08-17 University Of Oslo Bacterial growth media
EP3205209A1 (en) 2016-02-09 2017-08-16 Basf Se Mixtures and compositions comprising paenibacillus strains or metabolites thereof and other biopesticides
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
CN119454720A (zh) * 2016-03-24 2025-02-18 帕拉特克Spv2有限责任公司 用于治疗和预防艰难梭菌感染的方法
MY190858A (en) 2016-04-05 2022-05-12 Nch Corp Nutrient rich germinant composition and spore incubation method
US12097226B2 (en) 2016-04-05 2024-09-24 Nch Corporation System and method for using a single-serve nutrient spore composition for small scale farm applications
US10897922B2 (en) 2016-04-05 2021-01-26 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
BR112018071198A2 (pt) 2016-04-15 2019-04-24 Ascus Biosciences, Inc. métodos para melhorar a produção agrícola de aves pela administração de consórcios microbianos ou de cepas purificadas dos mesmos
WO2017182796A1 (en) * 2016-04-19 2017-10-26 Genome Research Limited Bacteriotherapy
EP3448398A4 (en) 2016-04-21 2019-12-18 Naked Biome, Inc. COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES
US10252145B2 (en) 2016-05-02 2019-04-09 Bao Tran Smart device
US11707493B2 (en) 2016-05-23 2023-07-25 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
WO2017210428A1 (en) * 2016-06-01 2017-12-07 Crestovo Llc Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders
KR102658297B1 (ko) 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017218889A1 (en) * 2016-06-16 2017-12-21 Ohio State Innovation Foundation Eubacterium probiotics and methods of treating or preventing heart disease
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) * 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201703552D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
SG11201900253TA (en) * 2016-07-13 2019-02-27 Ubiome Inc Method and system for microbial pharmacogenomics
GB201703548D0 (en) * 2017-03-06 2017-04-19 4D Pharma Plc Compositions comprising bacterial strains
KR101815692B1 (ko) * 2016-07-25 2018-01-16 주식회사 고바이오랩 구강 세균의 군집을 이용한 대사성 질환 진단용 바이오 마커
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018031545A1 (en) * 2016-08-11 2018-02-15 The Trustees Of The University Of Pennsylvania Compositions and methods for detecting oral squamous cell carcinomas
WO2018046485A1 (en) 2016-09-09 2018-03-15 Swecure Ab Use of butyricimonas and/or oxalobacter for treating irritable bowel syndrome
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
JP6927512B2 (ja) * 2016-10-26 2021-09-01 地方独立行政法人神奈川県立産業技術総合研究所 物体表面の抗菌性試験用菌液媒体
WO2018106844A1 (en) * 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
US20200061131A1 (en) * 2016-12-16 2020-02-27 Vedanta Biosciences, Inc. Methods and compositions for determining bacterial integrity
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
BR112019013125B1 (pt) * 2016-12-23 2022-02-08 Keio University Composições farmacêuticas compreendendo uma mistura bacteriana purificada
MX2019007760A (es) 2016-12-28 2020-02-10 Ascus Biosciences Inc Metodos, aparatos y sistemas para analisis de cepa de microorganismo de comunidades heterogeneas complejas con analisis rastreador, determinacion de relaciones funcionales e interacciones de estas, y sintesis de agrupaciones microbianas que incluyen agrupaciones microbianas dosificadas y agrupaciones microbianas inoculativas.
US11400121B2 (en) 2017-01-05 2022-08-02 The University Of Chicago Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
CN107058490B (zh) * 2017-01-12 2018-03-06 杨俊杰 肠道及口腔菌群多样性及差异性的分析方法
US10381105B1 (en) 2017-01-24 2019-08-13 Bao Personalized beauty system
KR102769558B1 (ko) * 2017-02-28 2025-02-19 킴벌리-클라크 월드와이드, 인크. 미생물총의 건강한 균형을 유지하기 위한 상승적 조성물
US10052026B1 (en) 2017-03-06 2018-08-21 Bao Tran Smart mirror
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
EP3388069B1 (en) 2017-04-12 2019-05-01 ETH Zurich Consortia of living bacteria useful for treatment of microbiome dysbiosis
MX389322B (es) 2017-04-28 2025-03-20 Native Microbials Inc Metodos para complementar dietas con alto consumo de granos y/o alto valor energetico en rumiantes, mediante la administracion de un bioensamble sintetico de microbios, o cepas purificadas de los mismos
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN110996917A (zh) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
US20200268017A1 (en) * 2017-06-20 2020-08-27 Cornell University Probiotic compositions and methods
AU2018309153A1 (en) * 2017-08-04 2020-03-19 Tarunmeet GUJRAL Roseburia hominis, Eubacterium eligens, and combinations thereof as biotherapeutics
CN107854495B (zh) * 2017-08-04 2021-04-13 青岛东海药业有限公司 凝结芽孢杆菌在制备降低血尿酸制剂中的应用
MX2020001501A (es) * 2017-08-06 2020-03-24 Second Genome Inc Streptococcus australis como bioterapeuticos.
US20200360450A1 (en) * 2017-08-07 2020-11-19 Finch Therapeutics, Inc. Treatment of liver disease by modulation of the microbiome
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
TW201920648A (zh) 2017-08-29 2019-06-01 美商艾弗洛生物科技股份有限公司 使用布勞特氏(blautia)菌株治療癌症
EP3675833B1 (en) 2017-08-29 2026-06-10 Chr. Hansen A/S Stable capsules with fecal microbiota or a culture of microorganisms
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
AU2018330322A1 (en) 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
EP3453395B1 (en) 2017-09-08 2023-10-18 Deutsches Rheuma-Forschungszentrum Berlin Anaeroplasmatales for use in the treatment or prevention of an inflammatory disorder of the digestive system
CN111132684A (zh) * 2017-09-26 2020-05-08 第二基因组股份有限公司 作为生物治疗药物的血孪生球菌
WO2019079629A1 (en) 2017-10-18 2019-04-25 Ascus Biosciences, Inc. IMPROVING POULTRY PRODUCTION BY ADMINISTERING A SYNTHETIC BIO-ASSEMBLY OF MICROBES OR PURIFIED STEM THEREFOR
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
FI128395B (en) * 2017-11-09 2020-04-30 Kemira Oyj Method for making a fibrous web
CN107653243B (zh) * 2017-11-15 2021-06-15 中国农业科学院农业基因组研究所 一种从肠道内容物中提取微生物宏基因组dna的方法
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
CN107828705A (zh) * 2017-12-31 2018-03-23 佛山市艳晖生物科技有限公司 一株解淀粉芽孢杆菌及其在防治孤独症上的应用
WO2019149266A1 (en) * 2018-02-02 2019-08-08 The Chinese University Of Hong Kong Fecal fungome and therapeutic efficacy of fecal microbiota transplantation
CN112105371B (zh) * 2018-02-09 2024-12-17 内斯托尔株式会社 脂多糖控制性肠道细菌及其用途
JP2021512638A (ja) * 2018-02-09 2021-05-20 学校法人慶應義塾 Ｃｄ８＋ｔ細胞の誘導のための組成物および方法
CN110211629A (zh) * 2018-02-11 2019-09-06 中国科学院昆明动物研究所 一种评估微生物群落宏基因（或普通生物群落宏遗传）多样性和相似性的概念和方法
EP3768302B1 (en) 2018-03-20 2025-05-07 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021519763A (ja) * 2018-03-29 2021-08-12 セレス セラピューティクス インコーポレイテッド 炎症性腸疾患を治療するための組成物及び方法
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
WO2019200271A1 (en) 2018-04-13 2019-10-17 White Dog Labs, Inc. An improved method for selecting probiotics
KR102225939B1 (ko) * 2018-04-19 2021-03-10 주식회사 고바이오랩 신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물
JP7351853B2 (ja) * 2018-04-30 2023-09-27 サンコー・エナジー・インコーポレイテッド 植物の非生物的ストレス抵抗力を増加させるための大環状テトラピロール化合物、組成物及び方法
CN110468061B (zh) 2018-05-11 2024-03-08 韩国亿诺生物有限公司 具有预防或治疗癌症的效果的新型菌株
CA3101242A1 (en) 2018-05-23 2019-11-28 Brigham Young University Bacteriophage compositions and kits and related methods
US11986502B2 (en) 2018-05-23 2024-05-21 Optium, LLC Bacteriophage compositions and kits and related methods
KR20210024481A (ko) * 2018-05-24 2021-03-05 세레스 테라퓨틱스, 인코포레이티드 설계된 박테리아 조성물 및 이의 용도
WO2019231712A1 (en) * 2018-05-29 2019-12-05 Stc.Unm Virus-like particle compositions and methods of using same
CA3102263A1 (en) * 2018-06-07 2019-12-12 Artugen Therapeutics Ltd. Methods and compositions for the treatment of c. difficile
EP3806874A1 (en) * 2018-06-14 2021-04-21 Rebiotix, Inc. Microbiota restoration therapy (mrt) compositions and methods of manufacture
JP2021527639A (ja) * 2018-06-19 2021-10-14 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 生物療法製品を含む剤形
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
US12226433B2 (en) 2018-08-06 2025-02-18 The Johns Hopkins University Treatment of irritable bowel syndrome with molybdenum
JP7558170B2 (ja) 2018-08-17 2024-09-30 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 腸内毒素症を減少させ、微生物叢を復元する方法
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
WO2020041581A1 (en) * 2018-08-23 2020-02-27 Cornell University Methods and compositions for preventing and treating inflammatory bowel disease and nonalcoholic fatty liver disease
US11401500B2 (en) 2018-08-29 2022-08-02 Nch Corporation System, method, and composition for incubating spores for use in aquaculture, agriculture, wastewater, and environmental remediation applications
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
WO2020061553A1 (en) 2018-09-21 2020-03-26 Emory University Using multiple heteroresistance to guide combination antibiotic regimens
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
CN109234195A (zh) * 2018-09-28 2019-01-18 邓州市汇海农业科技有限公司 一种稻田微生物复合菌剂
KR102135195B1 (ko) * 2018-10-08 2020-07-17 아주대학교산학협력단 테트라제노코커스 할로필러스를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
JP2022504185A (ja) * 2018-10-09 2022-01-13 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
IL328606A (en) * 2018-10-15 2026-07-01 Pharmabiome Ag Method for producing a consortium of bacterial strains
EP3870154A4 (en) 2018-10-22 2022-07-27 Research Institute at Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ANTIBIOTIC-INDUCED PATHOLOGIES USING PROBIOTICS IN BIOFILM STATE
US20220096566A1 (en) * 2018-11-09 2022-03-31 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of dysbiosis
JP2022512380A (ja) 2018-12-10 2022-02-03 ノヴォム バイオテクノロジーズ，インコーポレイテッド 高シュウ酸尿症を治療するための方法及び組成物
US12642826B2 (en) 2018-12-28 2026-06-02 General Probiotics, Inc. Combinations of engineered antimicrobial probiotics for treatment of gastrointestinal tract pathogens
AU2020211650B2 (en) 2019-01-25 2025-01-30 Nutrien Ag Solutions (Canada) Inc. Photosensitizer compounds, methods of manufacture and application to plants
JP7588289B2 (ja) 2019-02-15 2024-11-22 ニュートリエン・エージー・ソリューションズ・（カナダ）・インコーポレイテッド 植物の健康を増進するプロトポルフィリンｉｘ誘導体及びその使用
WO2020166708A1 (ja) * 2019-02-15 2020-08-20 コンビ株式会社 新規乳酸菌およびそれを含有する組成物
EP3930735A1 (en) 2019-02-26 2022-01-05 The Regents of the University of Colorado, a body corporate Method and composition for treating gastrointestinal inflammatory disorders
CN110195027B (zh) * 2019-03-08 2022-03-01 大连理工大学 烟草节杆菌zl-1及其堆肥低温发酵菌剂的制备方法与应用
US20220184153A1 (en) * 2019-03-25 2022-06-16 The State of Israel, Ministry of Agriculture&Rural Development, Agricltural Research Oganization(ARO Method of treating bovine mastitis
WO2020198503A1 (en) * 2019-03-26 2020-10-01 The Children's Medical Center Corporation Therapeutic microbiota for the treatment and/or prevention of dysbiosis
TW202108153A (zh) * 2019-05-10 2021-03-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
CN114041188A (zh) * 2019-05-23 2022-02-11 美国分子实验室公司 用于检测粪便样品中的幽门螺杆菌水平的方法
EP3958690A4 (en) * 2019-05-31 2023-04-19 South Dakota Board of Regents PROBIOTICS TO INHIBIT ENTERIC PATHOGENS
EP3975999A4 (en) 2019-06-03 2023-07-19 Theriva Biologics, Inc. ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES
KR102978329B1 (ko) 2019-06-03 2026-06-17 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 패혈증 및 괴사성 장염 유도된 신경발달 결핍의 예방을 위한 프리바이오틱 제형
WO2021011887A1 (en) * 2019-07-17 2021-01-21 University Of Utah Research Foundation Clostridia consortia compositions and methods of treating obesity, metabolic syndrome and irritable bowel disease
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
WO2021022066A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Compositions and methods for inhibiting bacterial virulence and flim-based device and method for antibiotic susceptibility testing
CN110358849A (zh) * 2019-07-30 2019-10-22 中国医学科学院北京协和医院 源于肠道的诊断胰腺炎的生物标志物、筛选方法及其用途
CN112438995A (zh) 2019-09-04 2021-03-05 台达电子工业股份有限公司 抑制具万古霉素抗药性肠球菌的益生菌及其组合与其用途
CA3153020A1 (en) * 2019-09-12 2021-03-18 Jothi Amaranath Govindan Compositions and methods for characterizing a microbiome
AU2020354581A1 (en) 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
EP4054609A1 (en) * 2019-11-04 2022-09-14 Vedanta Biosciences, Inc. Compositions and methods for enhancing immune checkpoint inhibitor therapy
US20230125810A1 (en) * 2019-11-27 2023-04-27 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
KR102215592B1 (ko) * 2019-12-11 2021-02-15 주식회사 에이치이엠 신규한 락토바실러스 퍼멘텀 hem 1036 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
EP4017462B1 (en) 2019-12-16 2026-04-01 Colgate-Palmolive Company Oral care compositions containing inulin
EP3838276A1 (en) * 2019-12-17 2021-06-23 Exeliom Biosciences Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
US12121553B2 (en) 2020-01-27 2024-10-22 General Probiotics, Inc. Compositions including probiotic bacteria for the expression and secretion of enterocins to control clostridia perfringens-induced necrotic enteritis in livestock and related methods
WO2021159068A1 (en) 2020-02-06 2021-08-12 Nch Corportion Composition and method of using germinative compounds in probiotics for inflammation reduction in humans
WO2021163212A1 (en) 2020-02-10 2021-08-19 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
EP4106779A4 (en) * 2020-02-18 2024-03-20 Memorial Sloan Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk of poor cancer survival
US20230172996A1 (en) * 2020-02-21 2023-06-08 Yoshikazu NAKAOKA Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension
EP4110269A4 (en) 2020-02-28 2024-01-17 Emory University PENTAGALLOYL GLUCOSE FROM SCHINUS PLANTS AND METHOD OF USE
TW202146036A (zh) * 2020-04-28 2021-12-16 香港中文大學 針對ｃｏｖｉｄ－１９的微生物的治療和診斷用途
WO2021221110A1 (ja) * 2020-04-29 2021-11-04 学校法人慶應義塾 Ｔｈ１細胞及び／又はＴｈ１７細胞の増殖又は活性化を誘導する小腸内細菌
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
NL2025863B1 (en) 2020-06-19 2022-02-17 Acad Medisch Ct Fecal matter for treatment of cachexia
EP4189063A4 (en) * 2020-07-28 2024-08-07 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL TRACT INFECTIONS
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
CN112040091B (zh) 2020-09-01 2023-07-21 先临三维科技股份有限公司 相机增益的调整方法和装置、扫描系统
US12553883B2 (en) 2020-09-11 2026-02-17 MarvelBiome, Inc. Methods and uses of microbiome compositions
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
KR102470808B1 (ko) * 2020-11-02 2022-11-28 주식회사 바이오미 염증성 장질환 예방 또는 치료용 조성물
AU2021388169A1 (en) * 2020-11-25 2023-07-13 Seres Therapeutics, Inc. Designed bacterial compositions for treating graft-versus-host-disease
US20240127925A1 (en) * 2021-02-03 2024-04-18 Tata Consultancy Services Limited Method and system for designing personalized therapeutics and diet based on functions of microbiome
TWI807646B (zh) * 2021-02-19 2023-07-01 星聚樊生物科技有限公司 中草藥多醣及其細菌組成物改善疾病的用途
KR102373888B1 (ko) * 2021-03-26 2022-03-15 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 변비 유무를 판별하는 방법 및 진단장치
KR102373886B1 (ko) 2021-03-26 2022-03-15 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 장염 유무를 판별하는 방법 및 진단 장치
CN113106042A (zh) * 2021-05-20 2021-07-13 广西壮族自治区兽医研究所 预防鸽形目念珠菌病的微生物菌剂、制剂及其制备方法和应用
NL2028324B1 (en) 2021-05-28 2022-12-12 Caelus Pharmaceuticals B V Insulin-sensitizing agent and butyrate-producing bacterium
EP4376836A1 (en) * 2021-07-30 2024-06-05 Oncomedics Compositions and methods for decontaminating and culturing a gastrointestinal tract sample
KR102583365B1 (ko) * 2021-08-11 2023-09-27 코스맥스 주식회사 마이크로코커스 안타르크티쿠스 균주 및 그의 피부 상태 개선 용도
JP2024544960A (ja) 2021-11-11 2024-12-05 コンチェルト バイオサイエンシーズ， インコーポレイテッド 皮膚疾患の処置のための微生物組成物
CN116135205A (zh) * 2021-11-16 2023-05-19 葡萄王生技股份有限公司 戊醣片球菌gkp4用于制备改善肌少症之口服组成物的用途
EP4183403A1 (en) * 2021-11-19 2023-05-24 Lietuvos Sveikatos Mokslu Universitetas Modification of fecal microbiota with capsules containing gram-positive bacteria
AU2022401678A1 (en) * 2021-12-02 2024-07-04 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
KR102438867B1 (ko) * 2022-03-11 2022-09-02 주식회사 바이오뱅크힐링 코프로코커스 캐터스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023132628A1 (ko) * 2022-01-04 2023-07-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN114317368B (zh) * 2022-01-05 2022-09-09 中国水产科学研究院南海水产研究所 一种利用盐渍四生球菌改善快速发酵鱼露风味的方法
EP4482332A1 (en) * 2022-02-23 2025-01-01 Société des Produits Nestlé S.A. Compositions and methods for reducing the occurrence of diarrhea by promoting blautia obeum in the gut microbiota
CA3255269A1 (en) * 2022-04-26 2023-11-02 Cedars-Sinai Medical Center METHANOGENS AND PREVOTELLA USED AS MICROBIAL BACTERIA INCREASING THE PROPORTION AND NORMAL RATES OF BACTERIA FOR THE TREATMENT AND DIAGNOSIS OF DISEASES
CN114965764B (zh) * 2022-05-18 2024-12-31 陕西安宁云生生物技术有限公司 便秘的诊断和治疗
CN115466690A (zh) * 2022-05-19 2022-12-13 同济大学 一种地芽孢杆菌新菌种及其培养方法和应用
WO2024026561A2 (en) * 2022-08-01 2024-02-08 Novel Biome Solutions Inc. Fecal microbiota transplant methods of manufacture
CN116790402B (zh) * 2023-01-14 2024-05-14 西北农林科技大学 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用
WO2025064408A1 (en) 2023-09-18 2025-03-27 The Broad Institute, Inc. Compositions and methods for treating cardiovascular disease
WO2025093777A1 (en) 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in the treatment and recurrence prophylaxis of clostridioides difficile infection and restoration of healthy microbiota
WO2025147266A1 (en) * 2024-01-06 2025-07-10 Jose Vega Method of mitigation of death from epileptic seizures
WO2025189001A2 (en) * 2024-03-06 2025-09-12 University Of Florida Research Foundation, Incorporated Methods of reducing occurrence of neurodevelopmental disorders
CN118360215B (zh) * 2024-05-22 2025-03-07 吉林省农业科学院(中国农业科技东北创新中心) 一种用于降低反刍动物甲烷排放量的菌剂及其制备方法以及含有该菌剂的配合饲料

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009864A (en) 1958-09-18 1961-11-21 Union Carbide Corp Process control
US3228838A (en) 1959-04-23 1966-01-11 Union Carbide Corp Preservation of biological substances
US3009861A (en) 1961-01-13 1961-11-21 Alderton Gordon Isolation of bacterial spores
US3608030A (en) 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US3892842A (en) * 1971-09-01 1975-07-01 Alza Corp Intrauterine contraceptive device for releasing steroid having double bond functionality
DE2414156A1 (de) * 1974-03-23 1975-09-25 Kleist Johann Georg Dr Arzneimittel zur beseitigung uraemischer symptome und verfahren zu seiner herstellung
US4077227A (en) 1976-11-12 1978-03-07 Regents Of The University Of Minnesota Method of freezing liquid material in which agglomeration is inhibited
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
FI59925C (fi) 1980-01-11 1981-11-10 Esko Viljo Nurmi Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae
US4780987A (en) * 1983-10-25 1988-11-01 Plant Genetics, Inc. Method for the preparation of hydrated, pregerminated seeds in gel capsules
US4655047A (en) 1985-03-25 1987-04-07 I.Q.F. Inc. Process for freezing or chilling
JPS61252212A (ja) 1985-04-12 1986-11-10 Mitsubishi Petrochem Co Ltd 高吸水性ポリマ−の製造方法
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
JP2733849B2 (ja) 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
US5045446A (en) 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
GB2233343B (en) 1989-06-30 1993-07-07 Farmos Oy A bacterial preparation for use in poultry
JP2961182B2 (ja) * 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5436002A (en) 1991-01-29 1995-07-25 Mycogen Corporation Bacillus thuringiensisisolate PS201T6 toxin
RU2035186C1 (ru) 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
WO1997008598A1 (de) 1995-08-25 1997-03-06 Gff Technopark Verfahren zur simultanen, digitalen phasenempfindlichen detektion von zeitaufgelösten, quasi-gleichzeitig erfassten datenarrays eines periodisch stimulierten systems
US5851545A (en) * 1995-08-25 1998-12-22 Sandoz Ltd. Insecticidal matrix and process for preparation thereof
EP0952773B1 (en) * 1995-09-15 2005-11-23 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
AUPO430496A0 (en) 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
US6024370A (en) 1997-07-03 2000-02-15 Rockshox, Inc. Damping cartridge for high performance suspension systems
US5965128A (en) 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6589771B1 (en) 1999-10-28 2003-07-08 Immunom Technologies, Inc. Methods for arousing dormant bacteria
US20030118547A1 (en) 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
US6613549B2 (en) 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2225600T3 (es) * 2000-09-22 2005-03-16 Galephar M/F Composicion semi-solida de isotretinoina.
CA2430292A1 (en) 2000-11-30 2002-06-06 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
KR100437497B1 (ko) * 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
EP1527164A4 (en) 2001-05-04 2006-02-01 Univ Florida CLONING AND SEQUENCING OF PYRUVATE CARBOXYLASE (PDC) GENES FROM BACTERIA AND USES THEREOF
ITMI20011632A1 (it) 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
CA2522957C (en) 2003-04-23 2013-10-22 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US7261861B2 (en) 2003-04-24 2007-08-28 Haemoscope Corporation Hemostasis analyzer and method
EP1473370A3 (en) 2003-04-24 2005-03-09 BioMerieux, Inc. Genus, group, species and/or strain specific 16S rDNA Sequences
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
AU2004265511A1 (en) 2003-08-18 2005-02-24 The Bio Balance Corporation A stable liquid probiotic composition, preparation and applications thereof
US20050048515A1 (en) 2003-08-29 2005-03-03 Garner Bryan E. Methods for detecting and quantifying specific probiotic microorganisms in animal feed
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
CN1913787B (zh) 2004-02-03 2014-11-26 增值研究合伙有限公司 在动物中促进生长的活体细菌的应用
US7632520B2 (en) 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
EP1815016B1 (en) 2004-11-01 2012-06-27 George Mason University Compositions and methods for diagnosing colon disorders
US7521201B2 (en) 2004-11-01 2009-04-21 Strategic Diagnostics Inc. Bacteriophages as selective agents
US20060188523A1 (en) 2005-01-10 2006-08-24 Zhiheng Pei Methods for diagnosing and treating chronic tonsillitis
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
DK1931363T3 (en) 2005-09-28 2016-02-22 Nordisk Rebalance As Treatment of IBD using both probiotic bacteria and fermented cereal as behandlingseffektorer
US8968721B2 (en) * 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP2035544A2 (en) 2006-05-18 2009-03-18 Biobalance Llc Bacterial strains, compositions including same and probiotic use thereof
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
JP5019563B2 (ja) * 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
JP2009541298A (ja) 2006-06-20 2009-11-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 胃腸障害を処置するための電子カプセル
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EE05459B1 (et) 2006-12-08 2011-08-15 Tartu �likool Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US8518873B2 (en) * 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
WO2009050794A1 (ja) 2007-10-16 2009-04-23 Fujitsu Limited 中継局装置、端末局装置、無線通信システムおよび負荷分散方法
US8236508B2 (en) 2008-01-29 2012-08-07 Drexel University Detecting and measuring live pathogens utilizing a mass detection device
US8021654B2 (en) * 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains
RU2010144789A (ru) 2008-04-01 2012-05-10 Метаметрикс Клиникал Лэборетери (Us) Процесс и способ мониторинга желудочно-кишечной микрофлоры
CN101264107A (zh) * 2008-05-09 2008-09-17 东北制药集团公司沈阳第一制药厂 地衣芽孢杆菌药物组合物及其制剂
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
EP2313773A1 (en) 2008-07-15 2011-04-27 Metanomics Health GmbH Means and methods diagnosing gastric bypass and conditions related thereto
CN102131928A (zh) 2008-08-26 2011-07-20 奥林巴斯株式会社 粪便试样的调制方法、粪便试样调制用溶液、及粪便采集用试剂盒
WO2010030997A1 (en) 2008-09-12 2010-03-18 The Washington University Regulating intestinal microbiota dependent signaling as a means to modulate body fat and/or weight loss
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
EP2367839A4 (en) 2008-11-03 2012-07-04 Univ Tufts METHOD AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORTS NUTRITION AND GROWTH
FR2938057B1 (fr) 2008-11-05 2013-05-17 Patrick Wozna Doseur a delta de pression
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
IT1393931B1 (it) * 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composizione di spore di batteri non patogeni
US20120128633A1 (en) 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
DK2419114T4 (da) 2009-05-01 2019-05-27 Uas Laboratories Llc Bakteriesammensætninger til profylakse og behandling af degenerative sygdomme
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US20120165215A1 (en) 2009-06-26 2012-06-28 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011046614A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
MX2012002039A (es) 2009-08-18 2012-04-11 Nestec Sa Una composicion nutricional que comprende cepas de lactococcus y que reduce los sintomas de la alergia, especialmente en infantes y en niños.
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
US20120149584A1 (en) 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
ES2660008T3 (es) 2009-09-23 2018-03-20 Thomas Julius Borody Terapia para infecciones entéricas crónicas
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20120276149A1 (en) 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
DK2498626T3 (en) 2009-11-12 2015-07-13 Nestec Sa FOOD COMPOSITION TO PROMOTE GAS MICROFLORAL BALANCE AND HEALTH
MX348611B (es) 2009-12-31 2017-06-21 Milton Trachtman Ira Forma de dosificación oral para usarse en el tratamiento de enfermedad inflamatoria de intestino debido a una infección bacteriana.
US9492487B2 (en) 2010-02-01 2016-11-15 Matthew Ryan Garner Microbial product containing multiple microorganisms
EP4663746A3 (en) 2010-02-01 2026-04-15 Ferring Microbiome Inc. Bacteriotherapy for clostridium difficile colitis
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
CN102939391A (zh) 2010-03-01 2013-02-20 国家农艺研究院 炎症性肠病的诊断方法
CA2791464A1 (en) 2010-03-01 2011-09-09 Institut National De La Recherche Agronomique Method of diagnosis of obesity
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011113801A1 (en) 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
BR112013001107B1 (pt) 2010-07-16 2022-01-25 The Board Of Trustees Of The University Of Arkansas Métodos e composições incluindo bactéria formadora de esporos para aumento da saúde dos animais
FI20105825A7 (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP2605746A2 (en) * 2010-08-19 2013-06-26 Merz Pharma GmbH & Co. KGaA Filler composition comprising beta-glucans
WO2012024638A2 (en) 2010-08-20 2012-02-23 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
US20130224164A1 (en) 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use
EP2646567A4 (en) 2010-10-04 2014-03-26 British Columbia Cancer Agency DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE FOR THE DIAGNOSIS OF GASTROINTESTINAL CARCINOMA
EP2662078A1 (en) 2010-11-10 2013-11-13 National Jewish Health Methods to Treat Allergic Conditions
US20120064592A1 (en) 2011-01-26 2012-03-15 Qteros, Inc. Biocatalysts synthesizing deregulated cellulases
CN103491969A (zh) 2011-02-09 2014-01-01 拉维沃公司 恢复和重建肠道微生物群的合生素组合物
TW201247875A (en) 2011-02-25 2012-12-01 Tricorder Diagnostics Llc Microbial signatures as indicators of radiation exposure
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
US9411937B2 (en) 2011-04-15 2016-08-09 Verinata Health, Inc. Detecting and classifying copy number variation
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120278201A1 (en) 2011-04-26 2012-11-01 Dwolla Corp. Location transaction processing system
US20120276056A1 (en) 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
US20120284637A1 (en) 2011-05-02 2012-11-08 John Edward Boyer Unified Virtual Group Calendar System
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
US20140348811A1 (en) 2011-07-27 2014-11-27 Max International, Llc Compositions comprising sugar-cysteine products
WO2013019896A1 (en) 2011-08-01 2013-02-07 Symbiotix Biotherapies, Inc. Platform for identifying and/or characterizing immunomodulatory agents
CA2851602C (en) 2011-08-30 2020-07-14 Academisch Medisch Centrum Method for preventing and/or treating insulin resistance
EP2756071B1 (en) 2011-09-14 2017-12-20 University Of Guelph Media supplements and methods to culture human gastrointestinal anaerobic microorganisms
US20130115232A1 (en) 2011-10-03 2013-05-09 Fred Hutchinson Cancer Research Center Methods for detecting graft-versus-host disease
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DK2750682T3 (en) 2011-10-11 2016-08-22 Achim Biotherapeutics Ab A composition comprising anaerobically cultured human intestinal flora
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
GB201201766D0 (en) 2012-02-01 2012-03-14 Imp Innovations Ltd Method
WO2013166031A1 (en) 2012-04-30 2013-11-07 The Washington University Method of isolating and characterizing microorganisms that are targets of host immune responses
US10130665B2 (en) 2012-05-18 2018-11-20 Genome Research Limited Method for identifying bacteria for bacteriotherapy
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US10722577B2 (en) 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
EP2684469A1 (en) 2012-07-13 2014-01-15 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth
US20140112985A1 (en) * 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
MX2015006491A (es) 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (en) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
US20160040215A1 (en) 2013-03-14 2016-02-11 Seres Therapeutics, Inc. Methods for Pathogen Detection and Enrichment from Materials and Compositions
JP2016519664A (ja) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
US9962415B2 (en) 2013-05-03 2018-05-08 Nestec S.A. Lachnospiraceae in the gut microbiota and association with body weight
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
EP3146065B1 (en) 2014-05-19 2024-11-13 Memorial Sloan Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
ES3010296T3 (en) 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
US20180200308A1 (en) 2015-07-08 2018-07-19 Seres Therapeutics, Inc. Methods of treating colitis
US20190247447A1 (en) 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
EP3379935A4 (en) 2015-11-25 2019-08-28 Memorial Sloan-Kettering Cancer Center METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法

Also Published As

Publication number Publication date
US20160243172A1 (en) 2016-08-25
US9446080B2 (en) 2016-09-20
JP2016509002A (ja) 2016-03-24
JP2024045100A (ja) 2024-04-02
US20250000915A1 (en) 2025-01-02
HK1219022A1 (zh) 2017-03-24
US9855303B2 (en) 2018-01-02
US9585921B2 (en) 2017-03-07
US20170196914A1 (en) 2017-07-13
EP2956006A2 (en) 2015-12-23
AU2018282348A1 (en) 2019-01-17
US20180200310A1 (en) 2018-07-19
CN110917220A (zh) 2020-03-27
AU2014212004B2 (en) 2018-09-20
HK1218559A1 (zh) 2017-02-24
EP3584308A2 (en) 2019-12-25
HK1218837A1 (zh) 2017-03-17
EP3584308A3 (en) 2020-03-04
US10967011B2 (en) 2021-04-06
EP2953474A2 (en) 2015-12-16
WO2014121302A2 (en) 2014-08-07
KR102553134B1 (ko) 2023-07-07
KR20150115888A (ko) 2015-10-14
AU2014212003A1 (en) 2015-09-24
AU2014212003C1 (en) 2020-07-16
US9011834B1 (en) 2015-04-21
US20240050490A1 (en) 2024-02-15
US20140328803A1 (en) 2014-11-06
JP6908332B2 (ja) 2021-07-28
US20210244774A1 (en) 2021-08-12
US10064900B2 (en) 2018-09-04
JP2016509003A (ja) 2016-03-24
EP2951285A4 (en) 2016-10-26
EP3587558A3 (en) 2020-03-04
JP2021181440A (ja) 2021-11-25
AU2020260564A1 (en) 2020-11-26
EP2951285A1 (en) 2015-12-09
RU2015137399A (ru) 2017-03-10
KR20210024683A (ko) 2021-03-05
US20190099455A1 (en) 2019-04-04
US12605415B2 (en) 2026-04-21
MX2015009991A (es) 2016-02-05
WO2014121301A1 (en) 2014-08-07
KR102222273B1 (ko) 2021-03-08
US20150093360A1 (en) 2015-04-02
CA2899926C (en) 2025-11-18
JP2019116488A (ja) 2019-07-18
NZ711771A (en) 2016-11-25
US20160184370A1 (en) 2016-06-30
AU2014212004A1 (en) 2015-09-24
US11730775B2 (en) 2023-08-22
US20160158294A1 (en) 2016-06-09
JP6479685B2 (ja) 2019-03-06
US10064901B2 (en) 2018-09-04
JP2019104742A (ja) 2019-06-27
CA2899925A1 (en) 2014-08-07
KR20230110367A (ko) 2023-07-21
US9180147B2 (en) 2015-11-10
US20160199423A1 (en) 2016-07-14
EP3587558A2 (en) 2020-01-01
WO2014121298A3 (en) 2014-10-09
EP2953474A4 (en) 2016-12-28
WO2014121298A2 (en) 2014-08-07
WO2014121302A3 (en) 2014-10-09
AU2020202312B2 (en) 2022-11-24
EP2956006A4 (en) 2017-02-22
US11185562B2 (en) 2021-11-30
JP6942745B2 (ja) 2021-09-29
RU2664479C2 (ru) 2018-08-17
AU2014212003B2 (en) 2020-01-02
CN105451561A (zh) 2016-03-30
US20220249578A1 (en) 2022-08-11
US20190192581A1 (en) 2019-06-27
CA3280244A1 (en) 2026-03-02
BR112015018625A2 (pt) 2017-09-19
AU2023201132A1 (en) 2023-06-01
JP7409743B2 (ja) 2024-01-09
AU2014212003A8 (en) 2015-10-22
MX2019014045A (es) 2020-02-05
BR122021010444B1 (pt) 2022-07-12
CA2899926A1 (en) 2014-08-07
AU2020202312A1 (en) 2020-04-23
AU2024202421A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
MX2019014045A (es) Composiciones y metodos.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
WO2016172658A3 (en) Microbiome regulators and related uses thereof
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
PH12016500862B1 (en) Autotaxin inhibitor compounds
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
WO2015143447A3 (en) Methods for treating neurological disorders
EP3255140C0 (en) LACTIC ACID BACTERIA, NATURAL IMMUNOACTIVATOR AND INFECTION PREVENTIVE/THERAPEUTIC AGENT DERIVED FROM SAID LACTIC ACID BACTERIA AND FOOD/DRINK
MX386374B (es) Composiciones farmacéuticas y alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesiten.
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2017015424A (es) Nanoparticulas para su uso como vacuna terapeutica.
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
BR112017026834A2 (pt) composição compreendendo vitaminas b e vitaminas c e seu uso
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
WO2016048007A8 (ko) D-갈락토오스를 포함하는 쿼럼센싱 저해제
EA033297B1 (ru) Терапевтические и питательные композиции для функциональных нарушений работы пищеварительной системы
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
EP3097918A4 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency

Legal Events

Date Code Title Description
FG Grant or registration